Please login to the form below
Ranbaxy
This page shows the latest Ranbaxy news and features for those working in and with pharma, biotech and healthcare.
Nearly half of all clinical trials not published
Drilling down into the data provides a mixed picture for the pharma industry - at one end of the scale is Ranbaxy, which has published no results for any of the 35
Latest news
-
Lundbeck challenge to EC pay-for-delay ruling fails
The four generics companies - Generics UK, Arrow, Alpharma and Ranbaxy - were fined around 52m, and those judgments have also been upheld by the General Court of the EU.
-
India denies Vertex patent on cystic fibrosis drug Orkambi
The patent was opposed by the Indian Pharmaceutical Alliance (IPA), a trade organisation representing India's larger pharmaceutical companies, including Cipla, Dr Reddy's Labs, Lupin, Nicholas Piramal, Ranbaxy and Wockhardt.
-
Heart drug sales continue downward spiral
The Swiss firm has managed to delay some generic forms of its drug onto the market until last year, when Ranbaxy was granted approval to sell its copycat form of valsartan.
-
Takeda to pay $2.4bn to settle Actos cancer suits
Actos has generated more than $16bn in sales since its 1999 release, according to court filings, but now also faces generic competition from India's Ranbaxy Laboratories.
-
Teva slapped with $512m fine on pay-for-delay deal
Ranbaxy Laboratories. ... Mylan and Ranbaxy, which are also defendants in the case, are not part of the settlement.
More from news
Approximately 6 fully matching, plus 92 partially matching documents found.
Latest Intelligence
-
Pharma deals in April 2015
The acquisition of this portfolio with sales of INR 150 Crores, will help Dr Reddy's maintain a competitive edge with fellow Indian rival Sun Pharmaceuticals, following its acquisition of Ranbaxy
-
Allergan and taking a specialised approach
But for the likes of GSK, Novartis and Lilly with their asset swap agreement, Forest Laboratories and its acquisition of Actavis, and the various dealings at Merck &Co, BMS, Ranbaxy and
-
Pharma deals during April 2014
The total cost of the all-stock acquisition is $4.0bn (an 18% premium), $3.2bn in stock and nearly $800m of Ranbaxy debt. ... Eclipsing all else will be restoring FDA confidence. To this end immediate remedial action will involve management restructuring
-
Deal Watch table for April 2014
Ranbaxy Laboratories/ Sun Pharmaceuticals. Acquisition. Generics including Lipitor, Nexium, Diovan. 3, 200.
-
Positive prospects for pharma in Latin America
Since 2008, more foreign companies such as Takeda, Daiichi Ranbaxy and others have been allowed to set operations in the country, increasing competition and consolidation.
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
Competition from within
Teva (Israel), CSL (Australia) and Aspen (South Africa) are notable exceptions, with the Indian generic giants Sun and Ranbaxy - which have since merged - the only representation from the ‘BRIC’ markets (Brazil,
-
Exploring MINT: Part 3 - Nigeria
At present, antiretroviral treatment is primarily funded by philanthropic organisations, with generic companies such as Indian Cipla, Hetero and Ranbaxy among those supplying low-cost generic ARVs to African governments.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- Europe’s cancer community publishes new report on transforming patient care
- EU outlines measures to mitigate antibiotic shortage across Europe
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Diversifying Healthcare AI with Federated Learning
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- EU to revise pharmaceuticals law amid antibiotic shortages
- European MPs call for urgent action against antimicrobial resistance
- The role of medical communications in building credibility for healthtech
PMHub
11 London
We live in a hyper-connected world. This has clear benefits for the health of our communities, our businesses and our...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
